To evaluate the diagnostic performance and clinical utility of 18F-fluciclovine PET/CT in patients with biochemical recurrence (BCR) of prostate cancer (PC).18F-Fluciclovine scans of 165 consecutive men with BCR after primary definitive treatment with prostatectomy (n?=?102) or radiotherapy (n?=?63) were retrospectively evaluated. Seventy patients had concurrent imaging with at least one other conventional modality (CT (n?=?31), MRI (n?=?31), or bone scan (n?=?26)). Findings from 18F-fluciclovine PET were compared with those from conventional imaging modalities. The positivity rate and impact of 18F-fluciclovine PET on patient management were recorded. In 33 patients who underwent at least one other PET imaging (18F-NaF PET/CT (n?=?12), 68Ga-PSMA11 PET/CT (n?=?5), 18F-DCFPyL PET/CT (n?=?20), and 68Ga-RM2 PET/MRI (n?=?5)), additional findings were evaluated.The overall positivity rate of 18F-fluciclovine PET was 67 %, which, as expected, increased with higher prostate-specific antigen (PSA) levels (ng/ml): 15 % (PSA?
View details for DOI 10.1007/s11307-021-01583-3
View details for PubMedID 33469884